在炎症性肠病中的改变内分泌系统基因表达 粘膜:炎症性肠病管理的新视角
Iulia Andreea Pelisenco1, Alessandro Salvi2, Giuseppina De Petro2
1Department of Pathology, Victor Babes National Institute of Pathology, Bucharest 050096, Romania.
World journal of gastrointestinal endoscopy
|February 17, 2026
概括
在炎症性肠病 (IBD) 患者中,内分泌系统 (ECS) 受到损害,关键基因表达在炎症性肠组织中发生变化. 对用于IBD治疗的大麻素进行进一步的研究是有必要的.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),涉及慢性胃肠道炎症.
- 内分泌大麻素系统 (ECS) 在维持肠道平衡和防止炎症方面发挥着至关重要的作用.
研究的目的:
- 为了研究IBD患者内分泌大麻素系统 (ECS) 的潜在损伤.
- 分析IBD患者和健康对照者的炎症和非炎症结肠粘膜中关键ECS成分的基因表达水平.
主要方法:
- 量化聚合酶链反应 (qPCR) 用于测量信使RNA (mRNA) 表达水平.
- 研究的基因包括大麻素受体 (CNR1,CNR2),酶 (FAAH,MGLL) 和信号分子 (GPR18,GPR55,PPARG,TRPV1).
- 分析了30名IBD患者的炎症 (IM) 和非炎症 (NIM) 结肠粘膜的对活检和17名非IBD对照.
主要成果:
- 在10个研究的ECS基因中,有6个在IBD患者中显示出失调.
- 与非炎症粘膜 (NIM) 和对照相比,FAAH,PPARG和TRPV1在炎症结肠粘膜 (IM) 中显著下调.
- 与NIM相比,在IM中CNR2和GPR55的调节率明显上升.
结论:
- 在患有炎症性肠病 (IBD) 的患者中,内分泌系统 (ECS) 显著受损.
- 这些发现表明,大麻素在治疗IBD方面可能发挥作用.
- 建议进行更大的队列研究,以进一步阐明大麻素在IBD中的治疗潜力.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
810
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
810
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
602
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
602
Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
935
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
935
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
538
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
538


